Regen BioPharma (RGBP) Stock Price, News & Analysis

Company Overview

Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. It engages in identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications, and immune cell suppression for autoimmune disease. The company is involved in the development of its products, and therapies, including HemaXellarate, a cellular therapeutic product of autologous stromal vascular fraction derived from adipose tissue; dCellVax, an autologous dendritic cell which is treated with an siRNA inhibitor of indoleamine-2,3-dioxygenase; tCellVax which is treated with siRNA to inhibit NR2F6 and the cells re-infused to the patient; DiffronC, uses proprietary siRNA in vivo to inhibit cancer growth and activate T cells; and DuroCAR comprising of CAR-T cells which is treated with an shRNA targeting the gene NR2F6. The company was incorporated in 2012 and is based in La Mesa, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.04 to $0.07
• 52-Week Range: N/A
• Volume: 10,740 shs
• Average Volume: 15,462 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RGBP Stock Analysis - Frequently Asked Questions

When did Regen BioPharma's stock split?

Regen BioPharma's stock split on the morning of Thursday, June 20th 2024.The 3-1 split was announced on Thursday, June 20th 2024. The newly created shares were payable to shareholders after the closing bell on Thursday, June 20th 2024. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

How do I buy shares of Regen BioPharma?

Shares of RGBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Regen BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Regen BioPharma investors own include Meta Platforms (META), Trans Global Group (TGGI), Exxe Group (AXXA), DraftKings (DKNG), Enzolytics (ENZC), Alcoa (AA) and Airborne Wireless Network (ABWN).

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:RGBP
• CIK: 1589150
• Web: www.regenbiopharmainc.com
• Phone: (619) 722-5505
• Fax: N/A
• Employees: 1
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A